|Bid||38.98 x 800|
|Ask||39.08 x 800|
|Day's Range||38.24 - 39.08|
|52 Week Range||34.98 - 47.50|
|Beta (5Y Monthly)||0.85|
|PE Ratio (TTM)||68.25|
|Earnings Date||Oct 25, 2022 - Oct 31, 2022|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||48.49|
Subscribe to Yahoo Finance Plus to view Fair Value for BSX
From biotech to managed care, companies are tackling new challenges in science and business. Our healthcare roundtable experts pick 12 stocks that could win.
Investors are optimistic about Boston Scientific's (BSX) impressive top-line results and notable acquisitions.
Boston Scientific Corporation (NYSE:BSX) has announced results from the PROTECTED TAVR clinical trial evaluating the SENTINEL™ Cerebral Protection System, which is designed to capture and remove embolic debris stemming from transcatheter aortic valve replacement (TAVR) before it can reach the brain and potentially cause a stroke. Outcomes were presented during a late-breaking clinical science session at the 34th Transcatheter Cardiovascular Therapeutics (TCT), the annual scientific symposium of